A Single-blind, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAY 3389934 Intravenous Infusions in Healthy Japanese Participants.
Latest Information Update: 14 Oct 2025
At a glance
- Drugs BAY 3389934 (Primary)
- Indications Blood coagulation disorders; Sepsis
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 03 Oct 2025 Status changed from not yet recruiting to recruiting.
- 22 Sep 2025 New trial record